title: Risk factors and outcomes of new-onset diabetes after transplant: single-centre experience.
abstract: OBJECTIVE
  We sought to study the prevalence, risk factors, and long-term prognosis of posttransplant diabetes mellitus.
  
  
  METHODS
  We studied all patients with end-stage renal disease without diabetic nephropathy who received a kidney transplant and were followed-up at our center since 1983 (n=218; age, 44.3 ± 13.1 y). Patients with new-onset diabetes after transplant were compared to kidney transplant recipients without risk factors for diabetes mellitus. Patients with new-onset diabetes after transplant were divided into subgroups according to time of onset (early; < 90 d vs late, ≥ 90 d).
  
  
  RESULTS
  In total, 73/218 patients (33%) developed new-onset diabetes after transplant. Patients with new-onset diabetes after transplant were significantly older (51.2 ± 11.4 vs 40.7 ± 12.5 y; P < .001) and had a tendency to have a higher body mass index (29.6 ± 8.7 vs 21.6 ± 7.8 kg/m2; P =.05) than those that did not have new-onset diabetes after transplant. In multivariate analysis, age (P < .001), hepatitis C virus infection (P < .05), family history of diabetes mellitus (P < .03), and tacrolimus use (P < .001) were independent risk factors. Five- and 10-year death censored patient survival rates were worse in those that had new-onset diabetes after transplant compared with controls (log rank, 0.04), whereas there was no difference in outcomes between the early and late subgroups.
  
  
  CONCLUSIONS
  The prevalence of new-onset diabetes after transplant was 33%. Age, body weight at time of transplant, tacrolimus use, family history of diabetes mellitus, and hepatitis C virus infection are independent risk factors for new-onset diabetes after transplant. New-onset diabetes after transplant has a negative effect on patient survival, irrespective of the time of onset and duration of diabetes.
authors.affiliation: Nephrology and Transplant Unit, Salmaniya Medical Complex, Faculty of Medicine and Medical Sciences, Arab Gulf University, Kingdom of Bahrain.
authors.forename: Sumaya M
authors.initials: SM
authors.lastname: Al-Ghareeb
authors.forename: Amgad E
authors.initials: AE
authors.lastname: El-Agroudy
authors.forename: Sameer M
authors.initials: SM
authors.lastname: Al Arrayed
authors.forename: Ahmed
authors.initials: A
authors.lastname: Al Arrayed
authors.forename: Hamad A
authors.initials: HA
authors.lastname: Alhellow
mesh_terms: D000328:Adult; D017677:Age Distribution; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000401:mortality; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000401:mortality* / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011183:Postoperative Complications / Q000401:mortality*; D015995:Prevalence; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus